Danaher Co. (NYSE:DHR) Shares Purchased by Coronation Fund Managers Ltd.

Coronation Fund Managers Ltd. grew its position in shares of Danaher Co. (NYSE:DHR) by 29.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,389 shares of the conglomerate’s stock after acquiring an additional 1,470 shares during the quarter. Coronation Fund Managers Ltd.’s holdings in Danaher were worth $1,596,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after purchasing an additional 2,998,161 shares during the period. Price T Rowe Associates Inc. MD raised its position in Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after acquiring an additional 1,619,586 shares in the last quarter. Capital International Investors lifted its stake in Danaher by 9.1% during the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after purchasing an additional 1,334,781 shares during the last quarter. Finally, Norges Bank bought a new stake in Danaher during the fourth quarter worth approximately $1,752,382,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Linda Filler sold 3,928 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the completion of the transaction, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The disclosure for this sale can be found here. Insiders have sold a total of 38,707 shares of company stock valued at $10,786,944 in the last three months. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

DHR traded down $0.01 on Friday, hitting $269.32. The company had a trading volume of 1,746,456 shares, compared to its average volume of 2,862,712. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company’s fifty day moving average price is $257.69 and its 200 day moving average price is $253.45. The stock has a market cap of $199.48 billion, a price-to-earnings ratio of 45.65, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.05 earnings per share. Equities analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on DHR shares. Jefferies Financial Group initiated coverage on Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. Barclays boosted their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Stifel Nicolaus lifted their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Finally, Robert W. Baird raised their target price on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Six investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $276.88.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.